Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inbrija for early morning OFF in Parkinson's disease
2026-526465-18-00Phase 3Authorised
- Sponsor
- Capital Region of Denmark
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of levodopa in Parkinson's disease (PD) (2 arms), sponsored by Capital Region of Denmark. Primary endpoint: Time to first PKG-defined ON state after morning dose. Planned start Jun 2026; status: authorised.
02
Drugs
levodopa
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2026-526465-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526465-18-00.